285 related articles for article (PubMed ID: 29623098)
1. High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease.
Kosmas CE; Martinez I; Sourlas A; Bouza KV; Campos FN; Torres V; Montan PD; Guzman E
Drugs Context; 2018; 7():212525. PubMed ID: 29623098
[TBL] [Abstract][Full Text] [Related]
2. High-Density Lipoprotein Functionality as a New Pharmacological Target on Cardiovascular Disease: Unifying Mechanism That Explains High-Density Lipoprotein Protection Toward the Progression of Atherosclerosis.
Favari E; Thomas MJ; Sorci-Thomas MG
J Cardiovasc Pharmacol; 2018 Jun; 71(6):325-331. PubMed ID: 29528874
[TBL] [Abstract][Full Text] [Related]
3. Lipids and cardiovascular disease: do the findings and therapy apply equally to men and women?
LaRosa JC
Womens Health Issues; 1992; 2(2):102-11; discussion 111-3. PubMed ID: 1617306
[TBL] [Abstract][Full Text] [Related]
4. High-density lipoprotein functionality in coronary artery disease.
Kosmas CE; Christodoulidis G; Cheng JW; Vittorio TJ; Lerakis S
Am J Med Sci; 2014 Jun; 347(6):504-8. PubMed ID: 24603157
[TBL] [Abstract][Full Text] [Related]
5. Environmental Factors Modifying HDL Functionality.
Kosmas CE; Sourlas A; Guzman E; Kostara CE
Curr Med Chem; 2022; 29(10):1687-1701. PubMed ID: 34269662
[TBL] [Abstract][Full Text] [Related]
6. Primary genetic disorders affecting high density lipoprotein (HDL).
Kosmas CE; Silverio D; Sourlas A; Garcia F; Montan PD; Guzman E
Drugs Context; 2018; 7():212546. PubMed ID: 30214464
[TBL] [Abstract][Full Text] [Related]
7. CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients.
Gille A; D'Andrea D; Tortorici MA; Hartel G; Wright SD
Arterioscler Thromb Vasc Biol; 2018 Apr; 38(4):953-963. PubMed ID: 29437574
[TBL] [Abstract][Full Text] [Related]
8. High-Density Lipoprotein Particles, Cell-Cholesterol Efflux, and Coronary Heart Disease Risk.
Asztalos BF; Horvath KV; Schaefer EJ
Arterioscler Thromb Vasc Biol; 2018 Sep; 38(9):2007-2015. PubMed ID: 30002062
[TBL] [Abstract][Full Text] [Related]
9. HDL-C: role as a risk modifier.
Barter P
Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
[TBL] [Abstract][Full Text] [Related]
10. High-density lipoprotein cholesterol efflux capacity is inversely associated with cardiovascular risk: a systematic review and meta-analysis.
Qiu C; Zhao X; Zhou Q; Zhang Z
Lipids Health Dis; 2017 Nov; 16(1):212. PubMed ID: 29126414
[TBL] [Abstract][Full Text] [Related]
11. Bariatric surgery improves lipoprotein profile in morbidly obese patients by reducing LDL cholesterol, apoB, and SAA/PON1 ratio, increasing HDL cholesterol, but has no effect on cholesterol efflux capacity.
Kjellmo CA; Karlsson H; Nestvold TK; Ljunggren S; Cederbrant K; Marcusson-Ståhl M; Mathisen M; Lappegård KT; Hovland A
J Clin Lipidol; 2018; 12(1):193-202. PubMed ID: 29146227
[TBL] [Abstract][Full Text] [Related]
12. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
13. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses.
van Capelleveen JC; Kastelein JJ; Zwinderman AH; van Deventer SJ; Collins HL; Adelman SJ; Round P; Ford J; Rader DJ; Hovingh GK
J Clin Lipidol; 2016; 10(5):1137-1144.e3. PubMed ID: 27678430
[TBL] [Abstract][Full Text] [Related]
14. The Yin and Yang of High-density Lipoprotein and Atherosclerotic Cardiovascular Disease: Focusing on Functionality and Cholesterol Efflux to Reframe the HDL Hypothesis.
Ganjali S; Watts GF; Banach M; Reiner Ž; Nachtigal P; Sahebkar A
Curr Med Chem; 2021; 28(29):6066-6081. PubMed ID: 33563147
[TBL] [Abstract][Full Text] [Related]
15. CETP Inhibition: Past Failures and Future Hopes.
Kosmas CE; DeJesus E; Rosario D; Vittorio TJ
Clin Med Insights Cardiol; 2016; 10():37-42. PubMed ID: 26997876
[TBL] [Abstract][Full Text] [Related]
16. High-density lipoprotein cholesterol efflux capacity and cardiovascular risk in autoimmune and non-autoimmune diseases.
Hafiane A; Favari E; Daskalopoulou SS; Vuilleumier N; Frias MA
Metabolism; 2020 Mar; 104():154141. PubMed ID: 31923386
[TBL] [Abstract][Full Text] [Related]
17. HDL (High-Density Lipoprotein) Cholesterol Efflux Capacity Is Associated With Incident Cardiovascular Disease in the General Population.
Ebtehaj S; Gruppen EG; Bakker SJL; Dullaart RPF; Tietge UJF
Arterioscler Thromb Vasc Biol; 2019 Sep; 39(9):1874-1883. PubMed ID: 31315436
[TBL] [Abstract][Full Text] [Related]
18. From HDL-cholesterol to HDL-function: cholesterol efflux capacity determinants.
Rhainds D; Tardif JC
Curr Opin Lipidol; 2019 Apr; 30(2):101-107. PubMed ID: 30672808
[TBL] [Abstract][Full Text] [Related]
19. Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor? New Insights From the Framingham Offspring Study.
Bartlett J; Predazzi IM; Williams SM; Bush WS; Kim Y; Havas S; Toth PP; Fazio S; Miller M
Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):206-212. PubMed ID: 27166203
[TBL] [Abstract][Full Text] [Related]
20. Serum high density lipoprotein cholesterol levels in Chinese healthy subjects and patients with certain diseases.
Cai HJ; Li ZX; Yang SM
Atherosclerosis; 1982 Jun; 43(2-3):197-207. PubMed ID: 7115460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
